Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Three-dimensional near-field microwave holography for tissue imaging.

International journal of biomedical imaging

Amineh RK, Khalatpour A, Xu H, Baskharoun Y, Nikolova NK.
PMID: 22550472
Int J Biomed Imaging. 2012;2012:291494. doi: 10.1155/2012/291494. Epub 2012 Apr 09.

This paper reports the progress toward a fast and reliable microwave imaging setup for tissue imaging exploiting near-field holographic reconstruction. The setup consists of two wideband TEM horn antennas aligned along each other's boresight and performing a rectangular aperture...

Cite
Amineh RK, Khalatpour A, Xu H, et al. Three-dimensional near-field microwave holography for tissue imaging. Int J Biomed Imaging. 2012;2012:291494doi: 10.1155/2012/291494.
Amineh, R. K., Khalatpour, A., Xu, H., Baskharoun, Y., & Nikolova, N. K. (2012). Three-dimensional near-field microwave holography for tissue imaging. International journal of biomedical imaging, 2012291494. https://doi.org/10.1155/2012/291494
Amineh, Reza K, et al. "Three-dimensional near-field microwave holography for tissue imaging." International journal of biomedical imaging vol. 2012 (2012): 291494. doi: https://doi.org/10.1155/2012/291494
Amineh RK, Khalatpour A, Xu H, Baskharoun Y, Nikolova NK. Three-dimensional near-field microwave holography for tissue imaging. Int J Biomed Imaging. 2012;2012:291494. doi: 10.1155/2012/291494. Epub 2012 Apr 09. PMID: 22550472; PMCID: PMC3328955.
Copy Download .nbib Format: NLM
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

The New England journal of medicine

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV.
PMID: 34986285
N Engl J Med. 2022 Jan 06;386(1):24-34. doi: 10.1056/NEJMoa2109970.

BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, has been shown to be safe and...

Cite
Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24-34doi: 10.1056/NEJMoa2109970.
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., Dalle, S., Arance, A., Grob, J. J., Srivastava, S., Abaskharoun, M., Hamilton, M., Keidel, S., Simonsen, K. L., Sobiesk, A. M., Li, B., Hodi, F. S., Long, G. V. (2022). Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. The New England journal of medicine, 386(1), 24-34. https://doi.org/10.1056/NEJMoa2109970
Tawbi, Hussein A, et al. "Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma." The New England journal of medicine vol. 386,1 (2022): 24-34. doi: https://doi.org/10.1056/NEJMoa2109970
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 06;386(1):24-34. doi: 10.1056/NEJMoa2109970. PMID: 34986285.
Copy Download .nbib Format: NLM
Dysplastic Barrett's lesion with white opaque substance and xanthoma.

VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy

Bechara R, Abaskharoun R, Manley P.
PMID: 31517164
VideoGIE. 2019 Jun 28;4(9):412-413. doi: 10.1016/j.vgie.2019.04.021. eCollection 2019 Sep.

No abstract available.

Cite
Bechara R, Abaskharoun R, Manley P. Dysplastic Barrett's lesion with white opaque substance and xanthoma. VideoGIE. 2019;4(9):412-413doi: 10.1016/j.vgie.2019.04.021.
Bechara, R., Abaskharoun, R., & Manley, P. (2019). Dysplastic Barrett's lesion with white opaque substance and xanthoma. VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 4(9), 412-413. https://doi.org/10.1016/j.vgie.2019.04.021
Bechara, Robert, et al. "Dysplastic Barrett's lesion with white opaque substance and xanthoma." VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy vol. 4,9 (2019): 412-413. doi: https://doi.org/10.1016/j.vgie.2019.04.021
Bechara R, Abaskharoun R, Manley P. Dysplastic Barrett's lesion with white opaque substance and xanthoma. VideoGIE. 2019 Jun 28;4(9):412-413. doi: 10.1016/j.vgie.2019.04.021. eCollection 2019 Sep. PMID: 31517164; PMCID: PMC6730479.
Copy Download .nbib Format: NLM
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

The New England journal of medicine

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV.
PMID: 34986285
N Engl J Med. 2022 Jan 06;386(1):24-34. doi: 10.1056/NEJMoa2109970.

BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, has been shown to be safe and...

Cite
Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24-34doi: 10.1056/NEJMoa2109970.
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., Dalle, S., Arance, A., Grob, J. J., Srivastava, S., Abaskharoun, M., Hamilton, M., Keidel, S., Simonsen, K. L., Sobiesk, A. M., Li, B., Hodi, F. S., Long, G. V. (2022). Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. The New England journal of medicine, 386(1), 24-34. https://doi.org/10.1056/NEJMoa2109970
Tawbi, Hussein A, et al. "Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma." The New England journal of medicine vol. 386,1 (2022): 24-34. doi: https://doi.org/10.1056/NEJMoa2109970
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 06;386(1):24-34. doi: 10.1056/NEJMoa2109970. PMID: 34986285.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries